BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8419196)

  • 1. Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers.
    Mannaerts B; Shoham Z; Schoot D; Bouchard P; Harlin J; Fauser B; Jacobs H; Rombout F; Coelingh Bennink H
    Fertil Steril; 1993 Jan; 59(1):108-14. PubMed ID: 8419196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism.
    Mannaerts B; Fauser B; Lahlou N; Harlin J; Shoham Z; Bennink HC; Bouchard P
    Fertil Steril; 1996 Feb; 65(2):406-10. PubMed ID: 8566271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism.
    Shoham Z; Mannaerts B; Insler V; Coelingh-Bennink H
    Fertil Steril; 1993 Apr; 59(4):738-42. PubMed ID: 8458489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjects.
    Matikainen T; De Leeuw R; Mannaerts B; Huhtaniemi I
    Fertil Steril; 1994 Jan; 61(1):62-9. PubMed ID: 8293846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females.
    Duijkers IJ; Klipping C; Boerrigter PJ; Machielsen CS; De Bie JJ; Voortman G
    Hum Reprod; 2002 Aug; 17(8):1987-93. PubMed ID: 12151425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absorption and uptake of recombinant human follicle-stimulating hormone through vaginal subcutaneous injections--a pharmacokinetic study.
    Hsu CC; Kuo HC; Hsu CT; Gu Q
    Reprod Biol Endocrinol; 2009 Oct; 7():107. PubMed ID: 19807931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of human follicle-stimulating hormone in gonadotropin-deficient men.
    Handelsman DJ; Turner L; Boylan LM; Conway AJ
    J Clin Endocrinol Metab; 1995 May; 80(5):1657-63. PubMed ID: 7745014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin.
    Di Stefano AF; Rusca A; Radicioni MM; Loprete L; Binelli D; Caccia G; Cometti B
    Clin Drug Investig; 2016 Dec; 36(12):1031-1044. PubMed ID: 27638053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone.
    le Cotonnec JY; Loumaye E; Porchet HC; Beltrami V; Munafo A
    Fertil Steril; 1998 Feb; 69(2):201-9. PubMed ID: 9496329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration.
    Porchet HC; le Cotonnec JY; Loumaye E
    Fertil Steril; 1994 Apr; 61(4):687-95. PubMed ID: 8150111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers.
    Voortman G; Mannaerts BM; Huisman JA
    Fertil Steril; 2000 Jun; 73(6):1187-93. PubMed ID: 10856481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy.
    Mannaerts BM; Rombout F; Out HJ; Coelingh Bennink H
    Hum Reprod Update; 1996; 2(2):153-61. PubMed ID: 9079410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis.
    Zwart AD; Urban RJ; Odell WD; Veldhuis JD
    Eur J Endocrinol; 1996 Oct; 135(4):399-406. PubMed ID: 8921820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions.
    Young J; Couzinet B; Chanson P; Brailly S; Loumaye E; Schaison G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3239-44. PubMed ID: 10999815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers.
    Mulders TM; Mink CP; Bobbink IW; Bennink HJ
    Contraception; 1998 Jul; 58(1):39-44. PubMed ID: 9743895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics.
    le Contonnec JY; Porchet HC; Beltrami V; Khan A; Toon S; Rowland M
    Fertil Steril; 1994 Apr; 61(4):679-86. PubMed ID: 8150110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.